title: Morbidity and mortality among patients with respiratory syncytial virus infection: a 2-year retrospective review.
abstract: Previous studies have demonstrated high morbidity and mortality for adult patients with respiratory syncytial virus (RSV) infection. We performed a retrospective, multicenter, two-year chart review of all patients (n = 334) testing positive for RSV by the ProFlu + (®) Influenza A/B and RSV assay (Hologic, Bedford, MA). We analyzed indicators of morbidity and mortality in children <6 years old, immunocompetent and immunosuppressed adults, and transplant patients. Significant morbidity and mortality was observed among hematopoietic stem cell transplant patients (7.3%, 60-day mortality), solid organ transplant patients (13.3%, 60-day mortality), and COPD patients (12.8%, 60-day mortality). Of the patients positive for RSV, 144 (43.1%) of 334 received antibacterials or antifungals following diagnosis. Of these patients, a bacterial or fungal pathogen was not recovered from 60% of cases. Despite advances in RSV treatment, certain populations appear to be inadequately treated, while others appear to be inappropriately treated with unnecessary antimicrobials.
authors.affiliation: Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology at Mayo Clinic, Rochester, MN, 55905, USA.
authors.forename: Neil W
authors.initials: NW
authors.lastname: Anderson
authors.affiliation: Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology at Mayo Clinic, Rochester, MN, 55905, USA.
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Binnicker
authors.affiliation: Division of Hospital Internal Medicine at Mayo Clinic, Jacksonville, FL, 32224, USA.
authors.forename: Dana M
authors.initials: DM
authors.lastname: Harris
authors.affiliation: Division of Hospital Internal Medicine at Mayo Clinic, Jacksonville, FL, 32224, USA.
authors.forename: Razvan M
authors.initials: RM
authors.lastname: Chirila
authors.affiliation: Division of Infectious Disease at Mayo Clinic, Jacksonville, FL, 32224, USA.
authors.forename: Lisa
authors.initials: L
authors.lastname: Brumble
authors.affiliation: Division of Biostatistics at Mayo Clinic, Rochester, MN, 55905, USA.
authors.forename: Jay
authors.initials: J
authors.lastname: Mandrekar
authors.affiliation: Department of Laboratory Medicine and Pathology at Mayo Clinic, Jacksonville, FL, 32224, USA. Electronic address: Hata.donna@mayo.edu.
authors.forename: D Jane
authors.initials: DJ
authors.lastname: Hata
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004363:Drug Utilization; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D029424:Pulmonary Disease, Chronic Obstructive; D018357:Respiratory Syncytial Virus Infections / Q000453:epidemiology* / Q000401:mortality* / Q000473:pathology; D012189:Retrospective Studies; D012307:Risk Factors; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents
keywords: Chronic obstructive pulmonary disease; RSV; Transplant